Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Consensus PT from Brokerages

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $11.13.

Several research analysts have recently weighed in on STRO shares. HC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of Sutro Biopharma in a research note on Monday, November 18th. Wells Fargo & Company cut their target price on shares of Sutro Biopharma from $5.00 to $4.00 and set an "equal weight" rating for the company in a research report on Wednesday, December 11th. JMP Securities restated a "market outperform" rating and set a $17.00 price target on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $8.00 price objective on shares of Sutro Biopharma in a report on Tuesday, December 10th.

Institutional Trading of Sutro Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the company. Suvretta Capital Management LLC boosted its position in shares of Sutro Biopharma by 3.8% during the 4th quarter. Suvretta Capital Management LLC now owns 7,462,495 shares of the company's stock valued at $13,731,000 after acquiring an additional 275,000 shares during the last quarter. Vestal Point Capital LP purchased a new position in Sutro Biopharma in the fourth quarter worth $4,729,000. Geode Capital Management LLC increased its stake in Sutro Biopharma by 7.7% in the third quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company's stock valued at $6,426,000 after acquiring an additional 132,015 shares during the last quarter. Parkman Healthcare Partners LLC raised its position in Sutro Biopharma by 0.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 1,727,925 shares of the company's stock valued at $3,179,000 after purchasing an additional 11,793 shares in the last quarter. Finally, State Street Corp lifted its stake in Sutro Biopharma by 5.2% during the third quarter. State Street Corp now owns 1,647,162 shares of the company's stock worth $5,699,000 after purchasing an additional 81,855 shares during the last quarter. 96.99% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Sutro Biopharma Stock Down 5.2 %

Sutro Biopharma stock traded down $0.07 during trading on Friday, hitting $1.28. The stock had a trading volume of 1,123,859 shares, compared to its average volume of 931,678. The stock's 50 day moving average is $1.82 and its two-hundred day moving average is $2.85. Sutro Biopharma has a 1 year low of $1.26 and a 1 year high of $6.13. The stock has a market cap of $105.55 million, a price-to-earnings ratio of -0.80 and a beta of 1.22.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.